Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Actuate Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Price Performance

Shares of ACTU stock opened at $2.48 on Friday. The firm has a 50 day moving average of $3.54 and a 200-day moving average of $5.59. Actuate Therapeutics has a 52 week low of $2.05 and a 52 week high of $11.99. The company has a market cap of $58.80 million, a price-to-earnings ratio of -2.36 and a beta of 0.85.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06.

Insider Activity at Actuate Therapeutics

In related news, Director Todd S. Thomson sold 280,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the sale, the director directly owned 904,795 shares of the company’s stock, valued at $5,247,811. This represents a 23.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 69.34% of the company’s stock.

Hedge Funds Weigh In On Actuate Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. ABS Direct Equity Fund LLC bought a new position in shares of Actuate Therapeutics in the 4th quarter worth approximately $40,000. Deutsche Bank AG lifted its stake in Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after purchasing an additional 8,051 shares in the last quarter. Barclays PLC boosted its stake in Actuate Therapeutics by 68.6% during the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after buying an additional 6,081 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Actuate Therapeutics in the 4th quarter worth $102,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.